indazoles has been researched along with gsk2269557 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Amour, A; Baldwin, IR; Cooper, AW; Deakin, AM; Down, K; Felton, LM; Guntrip, SB; Hamblin, JN; Hardy, C; Harrison, ZA; Jones, KL; Jones, P; Keeling, SE; Le, J; Livia, S; Lucas, F; Lunniss, CJ; Parr, NJ; Robinson, E; Rowland, P; Smith, S; Thomas, DA; Vitulli, G; Washio, Y | 1 |
| Begg, M; Cahn, A; Dunsire, L; Fuhr, R; Galinanes-Garcia, L; Hamblin, JN; Hessel, EM; Kirsten, AM; Leemereise, CN; Montembault, M; Sriskantharajah, S; Watz, H; Wilson, R | 1 |
| Begg, M; Cahn, A; Cui, Y; Hamblin, JN; Hessel, EM; Hogg, A; Khindri, S; Kornmann, O; Leemereise, C; Ludwig-Sengpiel, A; Montembault, M; Robertson, J; Wajdner, H; Yang, S | 1 |
| Cahn, A; Igarashi, H; Ino, H; Numachi, Y; Ogura, H; Terao, T; Wilson, R | 1 |
| Ahmad, S; Amour, A; Begg, M; Boyce, M; Cahn, A; Clark, J; Cui, Y; Deans, A; Dear, G; Fantom, K; Green, J; Hamblin, JN; Hessel, EM; Kielkowska, A; Montembault, M; Wilson, R; Worsley, S | 1 |
| Banham-Hall, E; Cahn, A; Eames, R; Hessel, EM; Leemereise, C; Templeton, A; Wilson, R | 1 |
| Cahn, AP; Georgiou, A; Harrell, AW; Hessel, EM; Marotti, M; Patel, A; Riddell, K; Taskar, KS; Taylor, M; Tracey, H; Wilson, R | 1 |
| Cahn, A; Fahy, WA; Hessel, EM; Homayoun-Valiani, F; Lowings, M; Marotti, M; Meeraus, WH; Robertson, J; Tabberer, M; Templeton, A; West, SL; Wilson, R | 1 |
| Amour, A; Edwards, CD; Graves, RH; Harrell, AW; Hessel, EM; Miller, NA; O'Brien, B; Patel, A; Robb, O; Taylor, E | 1 |
7 trial(s) available for indazoles and gsk2269557
| Article | Year |
|---|---|
Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Topics: Administration, Inhalation; Aged; Class I Phosphatidylinositol 3-Kinases; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indazoles; Indoles; Male; Middle Aged; Oxazoles; Piperazines; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Sputum; Treatment Outcome | 2017 |
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indazoles; Indoles; Male; Middle Aged; Oxazoles; Phosphatidylinositol 3-Kinases; Piperazines; Vital Capacity; Young Adult | 2018 |
Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects.
Topics: Administration, Inhalation; Adult; Area Under Curve; Asian People; Double-Blind Method; Drug Administration Schedule; Dry Powder Inhalers; Healthy Volunteers; Humans; Indazoles; Indoles; Male; Middle Aged; Oxazoles; Piperazines; Protein Kinase Inhibitors | 2019 |
Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Topics: Adult; Bronchoalveolar Lavage Fluid; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Indazoles; Indoles; Male; Middle Aged; Oxazoles; Phosphatidylinositols; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Smokers; Sputum | 2019 |
Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.
Topics: Administration, Inhalation; Double-Blind Method; Dry Powder Inhalers; Humans; Indazoles; Indoles; Oxazoles; Piperazines | 2019 |
Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Area Under Curve; Clarithromycin; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Healthy Volunteers; Humans; Indazoles; Indoles; Itraconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Models, Biological; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Prospective Studies; Retrospective Studies; Young Adult | 2020 |
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Topics: Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Humans; Indazoles; Indoles; Oxazoles; Phosphatidylinositol 3-Kinases; Piperazines; Pulmonary Disease, Chronic Obstructive | 2021 |
2 other study(ies) available for indazoles and gsk2269557
| Article | Year |
|---|---|
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
Topics: Administration, Inhalation; Animals; Asthma; Female; Humans; Indazoles; Indoles; Isoenzymes; Male; Microsomes; Molecular Docking Simulation; Ovalbumin; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rabbits; Rats; Rats, Sprague-Dawley; Respiratory Tract Diseases; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Th2 Cells | 2015 |
Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption.
Topics: Absorption, Physiological; Administration, Inhalation; Administration, Oral; Animals; Computer Simulation; Humans; Indazoles; Indoles; Models, Biological; Oxazoles; Piperazines; Rats | 2022 |